The Fleming Fund: Key Features of Design and Approach to Strengthening Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Tim Shorten und 5 weiteren Autor:innen. Beteiligte Einrichtung: Itad Ltd, Brighton, United Kingdom. Hauptthemen laut MEDLINE: Drug Resistance, Bacterial. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Department of Health and Social Care, Fleming Fund, UK National Institute for Health and Care Research.
Abstract (Originalsprache)
This paper examines the Fleming Fund as a major long-term investment in strengthening antimicrobial resistance (AMR) surveillance in low- and middle-income countries. Established by the UK Department of Health and Social Care in 2015, the Fund committed up to £498 million to support surveillance capacity across 25 countries in Africa and Asia through a One Health approach spanning human, animal and environmental health. The paper situates the Fleming Fund within wider global concern about AMR and highlights surveillance as essential for stewardship, policy and international coordination. It describes the Fleming Fund's design logic, governance arrangements, grant architecture and evolving strategic priorities, with particular attention to how the program combined laboratory strengthening, workforce development, data systems, quality assurance, sampling pathways and multisectoral coordination to generate credible and usable AMR data. The analysis also examines the Phase 2 shift from an initial emphasis on data generation toward greater attention to data interpretation, dissemination and use in policy and practice. Drawing on program documentation, evaluation evidence and stakeholder perspectives, the paper presents the Fleming Fund as an important case of large-scale surveillance system strengthening in resource-constrained settings. It argues that the Fund offers wider lessons on the time, coordination and institutional embedding required to move from externally supported capacity building toward sustainable national surveillance functions. These lessons are relevant to future AMR investments and to broader debates on global health security, health systems strengthening and One Health implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Itad Ltd, Brighton, United Kingdom.
- Independent Consultant, Redgrave, United Kingdom.
- Department of Health and Social Care, London, United Kingdom.
- Independent Consultant, Dar es Salaam, Tanzania.
- Independent Consultant, Bristol, United Kingdom.
- Department of Infectious Disease, Imperial College, London, United Kingdom.
ORCID-Profile: Tim Shorten, Ankur Gupta-Wright, Milena von Und Zur Mühlen, Evelyn Wesangula
Förderung
- UK Department of Health and Social Care
- Fleming Fund
- UK National Institute for Health and Care Research
- NIHR Imperial Biomedical Research Centre
- NIHR HealthTech Research Centre
- In Vitro Diagnostics
Zitieren
APA
Shorten, T., Clarke, J., Drake, A., Gupta-Wright, A., von Und Zur Mühlen, M., & Wesangula, E. (2026). The Fleming Fund: Key Features of Design and Approach to Strengthening Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag499
Vancouver
Shorten T, Clarke J, Drake A, Gupta-Wright A, von Und Zur Mühlen M, Wesangula E. The Fleming Fund: Key Features of Design and Approach to Strengthening Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag499
BibTeX
@article{Shorten2026,
author = {Shorten, Tim and Clarke, Jemima and Drake, Archibald and Gupta-Wright, Ankur and von Und Zur Mühlen, Milena and Wesangula, Evelyn},
title = {The Fleming Fund: Key Features of Design and Approach to Strengthening Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag499}
}
EUVIMED